Source comparison
Tesamorelin + Ipamorelin Blend: Administration Method Comparison
Subcutaneous injection (lyophilised blend reconstituted with bacteriostatic water) Yes. 2 mL per vial using cold diluent Daily or alternate-day (200–300 mcg per peptide per dose) 2–8°C refrigerated 28 days post-reconstitution Gold standard for research. Allows
This comparison does not assign a generated winner or score.
- Subcutaneous injection (lyophilised blend reconstituted with bacteriostatic water)
- Yes. 2 mL per vial using cold diluent
- Daily or alternate-day (200–300 mcg per peptide per dose)
- 2–8°C refrigerated
- 28 days post-reconstitution
- Gold standard for research. Allows precise dose control, maximises peptide stability when stored correctly, lowest contamination risk with proper aseptic technique.
- Subcutaneous injection (pre-mixed solution from compounding facility)
- No. Arrives ready-to-inject
- Daily or alternate-day
- 14–21 days (shorter than self-reconstituted due to earlier mixing date)
- Convenient but reduces control. Stability window begins at compounding date, not receipt date. Unknown transport conditions can compromise peptide before first use.
- Oral administration (experimental formulations)
- No
- Twice daily (due to poor bioavailability)
- Room temperature
- Manufacturer-dependent
- Not viable for rigorous research. Gastric peptidases degrade 85–95% of peptide before absorption; unreliable serum GH response makes data interpretation impossible.
- Intramuscular injection
- Yes. Same reconstitution as subcutaneous
- Daily
- No advantage over subcutaneous. Increased pain, higher risk of nerve or vessel damage, identical pharmacokinetics. Subcutaneous route is preferred in all published trials.